Members of the ACCC IO Institute Executive Committee discuss why care coordination and communication among the IO team, other providers, and the patient is critical for effective delivery of immunotherapy for cancer. (features Mark Faries, MD; Sanjiv Agarwala, MD; and Niesha Griffith, MS, RPh, FASHP)
SARS-CoV-2 and the resulting respiratory tract infection COVID-19 has upended our society and forcefully changed the way we care for patients. Since the emergence of the virus in early 2020, there have been questions surrounding the risk posed to patients with a cancer diagnosis and the safety of anticancer therapies.
Immuno-oncology (IO) has radically altered the patient care paradigm. One of most important changes attributed to IO is improvement in outcomes and lengthening of survival. This good news comes with multiple challenges, not least of which is the need for new and better communication and coordination among multiple specialties over time.
Download Article & Companion Guide
Learn how the microbiome could potentially be used to predict and enhance response to I-O therapy and to recognize patients who could be at risk for developing immune-related adverse events.